Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Pred...( SAN FRANCISCO June 9 /- Halozyme ...),Health

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced new Phase I data for the company's diabetes mellitus program at the American Diabetes Association's 68th Scientific Sessions. The data showed that combining the company's proprietary recombinant human hyaluronidase enzyme (rHuPH20) with Humulin R(R) (regular insulin human) or Humalog(R) (insulin lispro) yielded pharmacokinetics and glucodynamics that better mimicked physiologic prandial (mealtime) insulin release and activity than Humulin R or Humalog alone.

Key pharmacokinetic (PK) and glucodynamic (GD) improvements observed in the study include:
-- Significantly faster systemic absorption of each insulin, starting with

the first observation time point of three minutes after injection

-- Significantly faster and greater glucose lowering activity early after

injection

-- Significantly greater peak insulin levels for the same dose

administered

-- Significantly lower variability of key PK and GD variables across

subjects

-- rHuPH20 in combination with Humulin demonstrated statistically

significant improvement across all parameters when compared to Humalog

alone

By making mealtime insulins faster, i.e., shifting insulin exposure and glucose lowering activity to earlier times and away from late postprandial times, combination with rHuPH20 yielded a profile of insulin kinetics and activity more like that of natural, endogenous prandial insulin release.

Diabetes mellitus is an increasingly prevalent, costly condition associated
'/>"/>